Twist Bioscience officer proposes 2,245-share sale of Twist Bioscience stock

Published on 10/25/2026 at 13:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen raised its target to USD 190 from USD 115 on October 13, 2026. A 2,245-share sale filed October 23 involves Twist Bioscience stock.

Insider filing and analyst targets

Patrick Finn proposed selling 2,245 shares on October 23, 2026, for USD 302,153.21.
Fiscal third-quarter revenue rose 23.20 percent year over year to USD 118.38 million.
TD Cowen raised its target from USD 115 to USD 190 on October 13, 2026.

TWST, US90184D1000, Illustration mit AI erstellt.

Twist Bioscience officer Patrick Finn proposed selling 2,245 common shares for USD 302,153.21 on October 23, 2026, according to StockTitan. The filing says the transaction relates to restricted stock vesting and includes shares needed for an award-related tax obligation.

Revenue growth meets a valuation test

Twist Bioscience generated USD 118.38 million in fiscal third-quarter revenue, up 23.20 percent from the same quarter a year earlier, while adjusted earnings per share missed the USD 0.51 consensus with a USD 0.56 loss, MarketBeat reported on October 21, 2026. The revenue result exceeded the USD 114.55 million consensus by USD 3.83 million, but the loss keeps profitability central to the investment case.

What do the targets imply?

The analyst revisions are wide enough to make execution the key variable. Markets Insider reported that TD Cowen raised its target from USD 115 to USD 190 on October 13, 2026, while maintaining a Buy rating. Barclays had raised its target from USD 112 to USD 215 on October 7, 2026, and Guggenheim lifted its target from USD 107 to USD 212 on October 1, 2026.

Three dated developments

On October 1, 2026, Guggenheim raised its target from USD 107 to USD 212. On October 7, 2026, Barclays raised its target from USD 112 to USD 215. On October 23, 2026, Finn proposed the 2,245-share sale valued at USD 302,153.21.

Stock context for investors

Twist Bioscience develops synthetic DNA and related products through a silicon-based manufacturing platform, according to the company's investor-relations profile at Twist Bioscience. For investors, the combination of 23.20 percent fiscal third-quarter revenue growth and a USD 0.56 adjusted loss frames the next results as a test of whether expansion is translating into improved earnings.

Next milestones remain earnings-led

The company has scheduled investor presentations in its calendar, including the Baird 2026 Global Healthcare Conference on September 15, 2026, and its fiscal third-quarter results call on August 3, 2026. The latest operating figures and the October analyst revisions leave revenue conversion and adjusted profitability as the clearest measures for the next reporting cycle.

Twist Bioscience stock in context

Twist Bioscience is listed on Nasdaq under ticker TWST, and the proposed sale was filed for Nasdaq-listed common stock. The filing lists 62,707,424 shares outstanding alongside the proposed transaction.

The further course of trading is shown by the continuously updated real-time quote of Twist Bioscience stock.